Canada’s CGPA Installs New Leaders
Appoints New Chair And Vice-Chair From Pharmascience And Apotex
Canada’s off-patent industry association has looked to Pharmascience and Apotex for its new chair and vice-chair.
You may also be interested in...
Stada has appointed a new specialty head who will have global responsibility for the firm’s biosimilars business. Meanwhile, Hyloris has named a new business development chief and a generics industry veteran has joined Slayback’s board.
Canadian policymakers must learn “difficult lessons” from the coronavirus pandemic and support measures to bolster domestic production and secure the country’s position as part of the global supply chain, according to CGPA president Jim Keon.
With multiple Humira biosimilars slated for launch in the US next year, some simultaneously, a Vizient survey provides some insights into what could be the most important differentiating aspects. Generics Bulletin speaks to Steven Lucio, Vizient senior principal of pharmacy solutions, about the findings.